HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome
BackgroundColposcopy is recommended once human papillomavirus (HPV)16/18 infection is detected. However, not all HPV16/18-positive women will necessarily develop cervical lesions. Therefore, this study aimed to investigate the application of quantitative HPV16 E7 oncoprotein detection as a cervical...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1221962/full |
| _version_ | 1797680737415069696 |
|---|---|
| author | Xinmei Wang Guangnan Shuai Junhui Xu Meihua Liu Meihua Liu Jianguo Zhao Na Zhang Wenwen Zhang Pengpeng Qu |
| author_facet | Xinmei Wang Guangnan Shuai Junhui Xu Meihua Liu Meihua Liu Jianguo Zhao Na Zhang Wenwen Zhang Pengpeng Qu |
| author_sort | Xinmei Wang |
| collection | DOAJ |
| description | BackgroundColposcopy is recommended once human papillomavirus (HPV)16/18 infection is detected. However, not all HPV16/18-positive women will necessarily develop cervical lesions. Therefore, this study aimed to investigate the application of quantitative HPV16 E7 oncoprotein detection as a cervical cancer screening method for more efficient screening while minimizing unnecessary colposcopy.MethodsE7 oncoprotein (HPV16) was quantitatively detected in cervical exfoliated cells of HPV16-positive women. The levels of HPV16 E7 oncoprotein in different degrees of cervical lesions were compared, and the optimal cut-off value for identifying HSIL+ was determined by receiver operating characteristic (ROC) curve analysis. With a pathological diagnosis as the gold standard, the sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and Kappa value were calculated to verify the diagnostic value of the method. Women diagnosed with low-grade squamous intraepithelial lesions (LSIL) and normal women were followed up for 5 years to evaluate the predictive value of HPV16 E7 protein for disease progression/persistent infection.ResultsThe expression level of HPV16 E7 oncoprotein was positively correlated with the degree of the cervical lesion (r = 0.589, P < 0.01). The area under the ROC curve (AUC) was 0.817 (confidence interval: 0.729–0.904). The cut-off value of E7 oncoprotein for identifying HSIL+ was 8.68 ng/ml. The SEN, SPE, PPV, NPV, and Kappa values of HPV16 E7 oncoprotein for the identification of HSIL+ were 87.1%,70.0%, 87.1%, 70.0%, and 0.571, respectively, which were higher than those of ThinPrep cytology test (TCT). The SEN, SPE, PPV, and NPV of HPV16 E7 oncoprotein in predicting disease progression/persistent infection were 93.75%, 91.30%, 88.24%, and 95.45%, respectively.ConclusionThe quantitative detection of HPV 16 E7 oncoprotein can not only accurately screen cervical lesions but also achieve efficient colposcopy referral. Additionally, HPV16 E7 oncoprotein can accurately predict the progression of cervical lesions and persistent HPV infection. |
| first_indexed | 2024-03-11T23:34:26Z |
| format | Article |
| id | doaj.art-0601baca948e46c6ae0f486bec56cb91 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T23:34:26Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0601baca948e46c6ae0f486bec56cb912023-09-20T05:03:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12219621221962HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcomeXinmei Wang0Guangnan Shuai1Junhui Xu2Meihua Liu3Meihua Liu4Jianguo Zhao5Na Zhang6Wenwen Zhang7Pengpeng Qu8Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaWenjiang District People’s Hospital of Chengdu, Chengdu, Sichuan, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaTianjin Medical University, Tianjin, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaDepartment of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, ChinaBackgroundColposcopy is recommended once human papillomavirus (HPV)16/18 infection is detected. However, not all HPV16/18-positive women will necessarily develop cervical lesions. Therefore, this study aimed to investigate the application of quantitative HPV16 E7 oncoprotein detection as a cervical cancer screening method for more efficient screening while minimizing unnecessary colposcopy.MethodsE7 oncoprotein (HPV16) was quantitatively detected in cervical exfoliated cells of HPV16-positive women. The levels of HPV16 E7 oncoprotein in different degrees of cervical lesions were compared, and the optimal cut-off value for identifying HSIL+ was determined by receiver operating characteristic (ROC) curve analysis. With a pathological diagnosis as the gold standard, the sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and Kappa value were calculated to verify the diagnostic value of the method. Women diagnosed with low-grade squamous intraepithelial lesions (LSIL) and normal women were followed up for 5 years to evaluate the predictive value of HPV16 E7 protein for disease progression/persistent infection.ResultsThe expression level of HPV16 E7 oncoprotein was positively correlated with the degree of the cervical lesion (r = 0.589, P < 0.01). The area under the ROC curve (AUC) was 0.817 (confidence interval: 0.729–0.904). The cut-off value of E7 oncoprotein for identifying HSIL+ was 8.68 ng/ml. The SEN, SPE, PPV, NPV, and Kappa values of HPV16 E7 oncoprotein for the identification of HSIL+ were 87.1%,70.0%, 87.1%, 70.0%, and 0.571, respectively, which were higher than those of ThinPrep cytology test (TCT). The SEN, SPE, PPV, and NPV of HPV16 E7 oncoprotein in predicting disease progression/persistent infection were 93.75%, 91.30%, 88.24%, and 95.45%, respectively.ConclusionThe quantitative detection of HPV 16 E7 oncoprotein can not only accurately screen cervical lesions but also achieve efficient colposcopy referral. Additionally, HPV16 E7 oncoprotein can accurately predict the progression of cervical lesions and persistent HPV infection.https://www.frontiersin.org/articles/10.3389/fonc.2023.1221962/fullcervical cancercolposcopyhuman papillomavirusE7 oncoproteinhigh-grade cervical squamous intraepithelial lesionsThinPrep cytology test |
| spellingShingle | Xinmei Wang Guangnan Shuai Junhui Xu Meihua Liu Meihua Liu Jianguo Zhao Na Zhang Wenwen Zhang Pengpeng Qu HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome Frontiers in Oncology cervical cancer colposcopy human papillomavirus E7 oncoprotein high-grade cervical squamous intraepithelial lesions ThinPrep cytology test |
| title | HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome |
| title_full | HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome |
| title_fullStr | HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome |
| title_full_unstemmed | HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome |
| title_short | HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome |
| title_sort | hpv16 e7 oncoprotein test as a triage strategy for hpv16 positive women in cervical cancer screening long term follow up outcome |
| topic | cervical cancer colposcopy human papillomavirus E7 oncoprotein high-grade cervical squamous intraepithelial lesions ThinPrep cytology test |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1221962/full |
| work_keys_str_mv | AT xinmeiwang hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT guangnanshuai hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT junhuixu hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT meihualiu hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT meihualiu hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT jianguozhao hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT nazhang hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT wenwenzhang hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome AT pengpengqu hpv16e7oncoproteintestasatriagestrategyforhpv16positivewomenincervicalcancerscreeninglongtermfollowupoutcome |